Design and synthesis of novel and potent amide linked PPARγ/δ dual agonists

A series of potent amide linked PPARγ/δ dual agonists (1a) has been discovered through rational design. In the ZDF rat model of type 2 diabetes, compound (R)-3-[4-(3-{1-[(5-chloro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-ethyl}-5-fluoro-phenoxy)-2-ethyl-phenyl]-propionic acid (42) from this series has demonstrated glucose lowering efficacy comparable to the marketed PPARγ agonist rosiglitazone with less weight gain.

The synthesis and preclinical biological evaluation of a novel amide linked series of PPARγ/δ dual agonists are reported.Figure optionsDownload as PowerPoint slide